Summit Therapeutics is a biotechnology company focused on the discovery and development of novel antibiotic therapies
The company specializes in addressing complex infectious diseases, particularly those caused by antibiotic-resistant bacteria. Summit Therapeutics leverages its proprietary drug development platform to create innovative treatments aimed at improving patient outcomes and combating the growing threat of antibiotic resistance. Through its research and clinical programs, the company seeks to bring forward effective solutions to meet unmet medical needs in the realm of infectious diseases.
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
